Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

Author:

Lee Dae Hyun12ORCID,Kumar Abhishek3,Mohammed Turab45ORCID,Peres Lauren C.6,Alsina Melissa5,Bachmeier Christina4ORCID,Blue Brandon J.5,Brayer Jason5,Chandrasekhar Sanjay12ORCID,Grajales Cruz Ariel5,De Avila Gabe4,Elmariah Hany4ORCID,Faramand Rawan4,Freeman Ciara4ORCID,Jain Michael4ORCID,Khadka Sushmita4ORCID,Khimani Farhad4,Liu Hien4ORCID,Nishihori Taiga4ORCID,Oswald Laura B.7ORCID,Castaneda Puglianini Omar A.4ORCID,Shain Kenneth H.5,Smith Eric4,Baz Rachid C.5,Locke Frederick L.4,Oliveira Guilherme H.12,Alomar Mohammed12,Hansen Doris K.4

Affiliation:

1. 1Division of Cardiovascular Medicine, University of South Florida Morsani College of Medicine, Tampa, FL

2. 2Department of Cardio-Oncology, H. Lee Moffitt Cancer Center, Tampa, FL

3. 3Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, FL

4. 4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL

5. 5Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

6. 6Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL

7. 7Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center, Tampa, FL

Abstract

Abstract Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This was a retrospective single-center observational study of patients treated with ide-cel for RRMM. We included all consecutive patients who received standard-of-care ide-cel treatment at least 1-month follow-up. Baseline clinical risk factors, safety profile, and responses were examined based on the development of a cardiac event. A total of 78 patients were treated with ide-cel, and 11 patients (14.1%) developed cardiac events: heart failure (5.1%), atrial fibrillation (10.3%), nonsustained ventricular tachycardia (3.8%), and cardiovascular death (1.3%). Only 11 of the 78 patients had repeat echocardiogram. Baseline risk factors associated with the development of cardiac events included being female sex and having poor performance status, λ light-chain disease, and advanced Revised International Staging System stage. Baseline cardiac characteristics were not associated with cardiac events. During index hospitalization after CAR-T, higher-grade (≥grade 2) cytokine release syndrome (CRS) and immune cell–associated neurologic syndrome were associated with cardiac events. In multivariable analyses, the hazard ratio for the association of the presence of cardiac events with overall survival (OS) was 2.66 and progression-free survival (PFS) was 1.98. Ide-cel CAR-T for RRMM was associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity were associated with cardiac events after BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS; although because of the small sample size, the power to detect an association was limited.

Publisher

American Society of Hematology

Subject

Hematology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Idecabtagene-vicleucel;Reactions Weekly;2023-12-09

2. Guarding the Heart in an Era of “Tachy-CAR-T”;JACC: CardioOncology;2023-12

3. Long‐term survivorship care after CAR‐T cell therapy;European Journal of Haematology;2023-09-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3